ALK-Abello A/S 2025 IR
The report highlights ALK's strong performance in 2025, with revenue growing by 15% in local currencies to DKK 6,312 million and the EBIT margin reaching 26%. The company expanded its patient base by 500,000 to an estimated 3.1 million treated individuals, driven by the rollout of paediatric tablets and the launch of the needle-free adrenaline nasal spray neffy. In terms of sustainability, ALK reduced its Scope 1 and 2 greenhouse gas emissions by 11% compared to the 2022 baseline, aligning with its science-based targets. Additionally, the share of suppliers with validated science-based targets increased to 50%.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2025
Type: IR
Pages: 146
Back to company
ALK-Abello A/S
Annual Report
The report highlights ALK's strong performance in 2025, with revenue growing by 15% in local currencies to DKK 6,312 million and the EBIT margin reaching 26%. The company expanded its patient base by 500,000 to an estimated 3.1 million treated individuals, driven by the rollout of paediatric tablets and the launch of the needle-free adrenaline nasal spray neffy. In terms of sustainability, ALK reduced its Scope 1 and 2 greenhouse gas emissions by 11% compared to the 2022 baseline, aligning with its science-based targets. Additionally, the share of suppliers with validated science-based targets increased to 50%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees